The main developments in the ''ligand assay'' field in which I have be
en involved are traced. These include the original development of ''fi
rst generation'' competitive assays relying on radiolabeled analyte ma
rkers; the development of the first ''second generation'', noncompetit
ive (ultrasensitive) methods, which rely on the use of labeled (monocl
onal) antibodies and high specific activity nonisotopic labels (leadin
g to the transformation of the immunodiagnostic field in the 1980s); a
nd the development of the first ''third generation'' miniaturized, chi
p-based, microarray methods, which permit the simultaneous ultrasensit
ive measurement of many analytes in the same small sample. The latter-
applicable both to immunoassay and to DNA/RNA analysis-are likely to r
evolutionize the diagnostic and pharmaceutical fields in the next deca
de.